d development pipeline, and the therapeutic potential of antisense drugs for the treatment of cancer. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2008, which is on file with the SEC. Copies of this and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc.
Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.
Page: 1 2 3 Related biology technology :1
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Brazils top automakers to distribute 2 million copies of the Ethanol Handbook in partnership with the Brazilian Sugarcane Industry Association2
. Childrens Memorial Research Center, Chicago Becomes a Member of GeneGos MetaMiner Stem Cell Partnership Program3
. ViewRay Incorporated Closes $15M Tranche of Series B Financing and Announces Partnership with Siemens AG4
. US Oncology Clinical Development Attends Partnerships With CROs5
. Aviation partners to cut 500,000 tonnes of CO2 a year6
. ChemImage and Next Breath Structure Partnership to Validate Bioequivalence Testing for Nasal Spray Suspensions7
. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China8
. Van Andel Institute Joins the MetaMiner Oncology Partnership Program9
. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results10
. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*11
. The NIHR Biomedical Research Centre for Mental Health London has Joined the MetaMiner CNS Partnership Program